Healthcare stocks were declining pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.7% lower and the iShares Biotechnology ETF (IBB) down 0.5%.
Novo Nordisk (NVO) said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Novo Nordisk stock was down more than 2% premarket.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.